GL Capital and Zylox Tonbridge Back Lifetech to Build China Vascular Device Platform

Lifetech Scientific Corporation said it had brought in a joint strategic investment from GL Capital and Zylox-Tonbridge Medical Technology, a deal aimed at building a leading Chinese platform for vascular and structural heart disease interventions. The Hong Kong-listed medical device company announced on Nov. 6, 2026, that the investment would combine industrial and capital resources across the three parties. The investment is designed to integrate research and development, product portfolios and global commercialization resources, Lifetech said. The company described the transaction as a foundation for a full vascular and structural heart disease intervention platform in China, with the parties also…